Literature DB >> 18729185

Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions.

Jinhui Liao1, Xin Li, Amy J Koh, Janice E Berry, Nanda Thudi, Thomas J Rosol, Kenneth J Pienta, Laurie K McCauley.   

Abstract

Expression of parathyroid hormone-related protein (PTHrP) correlates with prostate cancer skeletal progression; however, the impact of prostate cancer-derived PTHrP on the microenvironment and osteoblastic lesions in skeletal metastasis has not been completely elucidated. In this study, PTHrP overexpressing prostate cancer clones were stably established by transfection of full length rat PTHrP cDNA. Expression and secretion of PTHrP were verified by western blotting and IRMA assay. PTHrP overexpressing prostate cancer cells had higher growth rates in vitro, and generated larger tumors when inoculated subcutaneously into athymic mice. The impact of tumor-derived PTHrP on bone was investigated using a vossicle co-implant model. Histology revealed increased bone mass adjacent to PTHrP overexpressing tumor foci, with increased osteoblastogenesis, osteoclastogenesis and angiogenesis. In vitro analysis demonstrated pro-osteoclastic and pro-osteoblastic effects of PTHrP. PTHrP enhanced proliferation of bone marrow stromal cells and early osteoblast differentiation. PTHrP exerted a pro-angiogenic effect indirectly, as it increased angiogenesis but only in the presence of bone marrow stromal cells. These data suggest PTHrP plays a role in tumorigenesis in prostate cancer, and that PTHrP is a key mediator for communication and interactions between prostate cancer and the bone microenvironment. Prostate cancer-derived PTHrP is actively involved in osteoblastic skeletal progression. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18729185      PMCID: PMC3979464          DOI: 10.1002/ijc.23602

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  52 in total

1.  Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.

Authors:  Y L Ma; R L Cain; D L Halladay; X Yang; Q Zeng; R R Miles; S Chandrasekhar; T J Martin; J E Onyia
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

2.  Parathyroid hormone-related peptide stimulates proliferation of highly tumorigenic human SV40-immortalized breast epithelial cells.

Authors:  C Cataisson; M Lieberherr; M Cros; C Gauville; A M Graulet; J Cotton; F Calvo; M C de Vernejoul; J Foley; Z Bouizar
Journal:  J Bone Miner Res       Date:  2000-11       Impact factor: 6.741

3.  Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling.

Authors:  Qinghua Zeng; Shenglin Li; Douglas B Chepeha; Thomas J Giordano; Jong Li; Honglai Zhang; Peter J Polverini; Jacques Nor; Jan Kitajewski; Cun-Yu Wang
Journal:  Cancer Cell       Date:  2005-07       Impact factor: 31.743

4.  Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines.

Authors:  J L Sanders; N Chattopadhyay; O Kifor; T Yamaguchi; R R Butters; E M Brown
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

Review 5.  Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.

Authors:  Philippe Clézardin; Frank H Ebetino; Pierrick G J Fournier
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

6.  Functional parathyroid hormone receptors are present in an umbilical vein endothelial cell line.

Authors:  C M Isales; B Sumpio; R J Bollag; Q Zhong; K H Ding; W Du; J Rodriguez-Commes; R Lopez; O R Rosales; J Gasalla-Herraiz; R McCarthy; P Q Barrett
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-09       Impact factor: 4.310

7.  Bone turnover mediates preferential localization of prostate cancer in the skeleton.

Authors:  Abraham Schneider; Linda M Kalikin; Ana C Mattos; Evan T Keller; Matthew J Allen; Kenneth J Pienta; Laurie K McCauley
Journal:  Endocrinology       Date:  2005-01-06       Impact factor: 4.736

Review 8.  Osteoblasts in prostate cancer metastasis to bone.

Authors:  Christopher J Logothetis; Sue-Hwa Lin
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

9.  Parathyroid hormone-related peptide is a potent tumor angiogenic factor.

Authors:  K Akino; A Ohtsuru; K Kanda; A Yasuda; T Yamamoto; Y Akino; S Naito; M Kurokawa; N Iwahori; S Yamashita
Journal:  Endocrinology       Date:  2000-11       Impact factor: 4.736

10.  Parathyroid hormone-related protein as a growth regulator of prostate carcinoma.

Authors:  K M Dougherty; E A Blomme; A J Koh; J E Henderson; K J Pienta; T J Rosol; L K McCauley
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

View more
  46 in total

Review 1.  Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  Engraftment and bone mass are enhanced by PTHrP 1-34 in ectopically transplanted vertebrae (vossicle model) and can be non-invasively monitored with bioluminescence and fluorescence imaging.

Authors:  Blake Eason Hildreth; Michelle M Williams; Katarzyna A Dembek; Krista M Hernon; Thomas J Rosol; Ramiro E Toribio
Journal:  Transgenic Res       Date:  2015-08-14       Impact factor: 2.788

3.  Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo.

Authors:  Jessica K Simmons; Wessel P Dirksen; Blake E Hildreth; Carlee Dorr; Christina Williams; Rachael Thomas; Matthew Breen; Ramiro E Toribio; Thomas J Rosol
Journal:  Prostate       Date:  2014-07-07       Impact factor: 4.104

4.  A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone.

Authors:  Parisa Hesami; Boris M Holzapfel; Anna Taubenberger; Martine Roudier; Ladan Fazli; Shirly Sieh; Laure Thibaudeau; Laura S Gregory; Dietmar W Hutmacher; Judith A Clements
Journal:  Clin Exp Metastasis       Date:  2014-02-08       Impact factor: 5.150

5.  Animal and cellular models of hepatocellular carcinoma bone metastasis: establishment and characterisation.

Authors:  Rui Hou; Yu-Wei Wang; Hui-Fang Liang; Zhan-Guo Zhang; Zhi-Min Liu; Bin-Hao Zhang; Bi-Xiang Zhang; Xiao-Ping Chen
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-28       Impact factor: 4.553

6.  Pre-clinical mouse models of human prostate cancer and their utility in drug discovery.

Authors:  Serk In Park; Sun Jin Kim; Laurie K McCauley; Gary E Gallick
Journal:  Curr Protoc Pharmacol       Date:  2010-12

7.  Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts.

Authors:  Kosuke Mizutani; Sudha Sud; Kenneth J Pienta
Journal:  J Cell Biochem       Date:  2009-03-01       Impact factor: 4.429

Review 8.  MicroRNAs in the control of metastatic bone disease.

Authors:  Gillian Browne; Hanna Taipaleenmäki; Gary S Stein; Janet L Stein; Jane B Lian
Journal:  Trends Endocrinol Metab       Date:  2014-05-05       Impact factor: 12.015

Review 9.  Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate.

Authors:  Cristina Sobacchi; Eleonora Palagano; Anna Villa; Ciro Menale
Journal:  Front Bioeng Biotechnol       Date:  2017-05-17

Review 10.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.